Introduction
Completion of the human genome project has ushered in a new age of molecular medicine. Moreover, the continued utilization, refinement and further development of genomic and postgenomic molecular technologies opens up exciting therapeutic possibilities with respect to a wide array of human diseases and disorders. [1] [2] [3] Among these is gene therapy or gene transfer. Historically, because of the uncertainties concerning the long-term impact of manipulation of genetic material on cellular and organismal biology, gene therapy has, until relatively recently, been reserved primarily as a treatment option for life-threatening diseases such as cancer and other acquired and hereditary disorders where few other effective therapies are available. For such life-threatening applications, the risk/benefit ratio intrinsic to gene transfer was considered to be acceptable. However, the public perception of gene transfer, as well as the regulatory oversight of this technology was dramatically altered as a result of the death of a young volunteer in a clinical trial in 1999. In that trial, a young man named Jesse Gelsinger was being treated to correct a metabolic disorder due to a deficiency of ornithine transcarbamylase (OTC) in 1999. [4] [5] [6] The patient died within 48 h of the intrahepatic administration of a recombinant adenoviral vector containing the OTC gene. Despite the unfortunate circumstances surrounding this event and the ensuing regulatory proposals/ changes, 5, 7, 8 there are still around 400-500 gene therapy trials being conducted worldwide. 5, 7 Naturally, the increased molecular understanding that has accompanied the genomic technological revolution has important implications for the improved understanding, diagnosis and treatment of erectile dysfunction as well. In fact, several different groups are currently pursuing gene therapy/transfer as a new treatment modality for erectile dysfunction. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The first preclinical reports of gene therapy for the treatment of erectile dysfunction predate the Gelsinger tragedy. These initial studies, conducted in the late 1990's documented the efficacy of gene transfer in the treatment of diminished erectile capacity in the rat model in vivo. 9, 10, 19 Since the appearance of these seminal publications there has been a steady, albeit slow, stream of papers on this subject, mainly from US laboratories, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] but a more recent report indicates that gene therapy is being considered in Asia as well. 17 When coupled with the sophisticated molecular information and technologies that are now available (ie, Functional genomics), gene transfer affords one the opportunity to affect virtually any aspect of the erectile process (at the end organ level) by selectively altering the expression of a given molecular target. The strategies that have been thus far utilized can be classified into two broad categories. First, those that correct the erectile deficit by increasing the supply/strength of the erectile stimulus. This can be achieved by increasing the amount/expression of a relevant endogenous vasomodulator of the erectile process through a variety of mechanisms (see Figure 1) . Alternatively, one can alter the tissue or end organ demand for a given erectile stimulus, using a variety of strategies to make the corporal tissue more sensitive to a relaxing stimulus (see Figure 1) . Thus, by altering the physiological supply and demand of erectile apparatus one can, both in theory and in practice (at least at the preclinical level) modulate and restore erectile capacity.
In this regard, a variety of gene therapy/transfer strategies have been tried thus far. Most of these have focussed, for obvious reasons, on the NO/ guanylate cyclase/cGMP pathway. However, other approaches include genetic manipulation of nerve and vascular growth factors, the cAMP cascade (ie, CGRP receptor), the calcium sensitization pathway and potassium channel gene expression (a cellular convergence point for mediating the effects of all of the above). Cell-based gene therapy approaches are also being evaluated. It should also be emphasized that unless otherwise indicated, all of the studies below have utilized the rat model, where a single intracavernous injection of the genetic material/ genetically modified cells is made into the penis, and all of the experiments are subsequently conducted.
Below, the field of gene therapy for the treatment of erectile dysfunction is reviewed, and some new frontiers for gene therapy/transfer are identified. The variety of vectors and physiological end points thus far used are summarized in Table 1 .
Gene therapy strategies that modulate the NO/ guanylate cyclase/cGMP pathway As evident from numerous laboratory investigations, as well as the clinical success of Viagra, it is clear that the nitrergic system plays a critical role in the normal erectile process. Thus, the NO synthetic pathway/biochemical cascade seems a logical molecular target for gene therapy, and of course falls in the general supply-side category of therapeutic possibilities. 9, [11] [12] [13] [14] The approaches tried thus far are reviewed below. The rationale is that overexpression of an important endogenous smooth muscle relaxant/vasodilator will assist with the diminished erectile response (ie, relaxation) characteristic of erectile dysfunction in many impotent patients.
Gene therapy with NOS isoforms
The strategy thus far has been to target one of the nitric oxide synthase (NOS) isoenzymes known to be present in the penis. The rationale for this is that as elsewhere in the body, NOS in the penis is responsible for synthesizing NO from L-arginine and molecular oxygen. There are three known NOS isoforms, and they have all been targeted; nNOS (neuronal NOSF in the rat PnNOS (penile NOS); 4 ), eNOS (endothelial NOS; 11, 12 ) and iNOS (inducible NOS isoform found in macrophages, smooth muscle cells, etc.; 9, 14 ). The effects observed with iNOS transfection appear as early as 2 days post-injection, 14 and have now been shown to last for up to 10 days after a single injection. 9 In both cases, there was a statistically significant increase in the cavernous nerve stimulated intracavernous pressure (ICP) response in animals receiving the gene therapy treatment. Similar observations have been made utilizing an Ad (adenovirus)/eNOS vector. That is, a physiologically significant effect on the nerve stimulated intracavernous pressure response was observed within 1 day of transfection. 11 Importantly, the pharmacological responses to intracavernous injection of zapranist (a cGMP PDE inhibitor) and acetylcholine were also enhanced; again, this may indicate that gene therapy can be combined with more traditional forms of pharmacological therapy. Moreover, subsequent studies by these same investigators have shown that the duration of Ad/eNOS gene therapy can be extended for up to 5 days (note that longer time points were not examined; 12 ). In addition, expression of the reporter gene betagalactosidase (ie, b-Gal), using the same Ad vector lasted for up to 60 days.
Most recently, 13 PnNOS (the penile-specific variant of nNOS) was transfected in rats using a 'gutless' (ie, replication incompetent) Ad vector, as well as a plasmid. The main goal of these studies was two-fold: (1) to increase transfection efficiency and reduce the immunogenic potential by using a modified Ad vector, and (2) to reduce the required viral load, by increasing the transfection efficiency with electroporation techniques. Comparisons with naked DNA plasmids were made in parallel. In these studies, statistically significant, and apparently physiologically relevant in vivo effects were observed for up to 18 days after a single injection of either plasmid/PnNOS or AdV/PnNOS; that is, elevated nerve stimulated intracavernous pressure responses were observed. Furthermore, expression of the b-Gal reporter gene was observed for up to 56 and 60 days postinjection with plasmid and AdV, respectively. Thus, electroporation (ie, application of electrical current across the injection site), was shown to increase both the apparent transfection efficiency and the duration of the effect of both plasmid and adenoviral-mediated gene transfer techniques.
The main limitation to these studies with NOS gene transfer may well be the relatively short duration of the physiological effect, although it appears that the in vivo effects may be significant at latter time points with a greater number of experimental observations (ie, up to 30 days, consistent with the statistical significance of the bGal expression data; Fig. 6 , Magee et al 13 ) . The explanation for the relatively short duration of efficacy is undetermined, but may be related to either the presence of even the 'gutless' viral vector or perhaps tight cellular regulation of the gene product. While no adverse immunologic, histologic or circulatory effects were observed, the potential long-term side effects of over-expression of the pleiotropic cytokine product (ie, NO) are not known. Lastly, the possibility of priapism seems to be a real concern with this approach, particularly with respect to iNOS (see Table 1 ).
Antisense oligonucleotide therapy with PDE V
An abstract was recently published in Chinese indicating that transfection of cultured human corporal smooth muscle cells with antisense oligonucleotides might also be possible. While the The most recent unpublished data from our group indicates that the physiological effect on ICP lasts for up to 6 months in the aged rat model, and up to 4 months in an experimentally diabetic rat model. Also note that an increased ICP to NS refers to a statistically significant increase over that observed in an untreated age-matched control rat. In general, the responses observed in the gene therapy treated rats was similar to that observed in young animals. c Since submission of the original manuscript, Bivalacqua et al 38 have published a paper in which superoxide dismutase (SOD) was tested (see note added in proof).
critique of this entire paper will be limited to the abstract, it seems worth including in this report, because of its potential implications to the field. 17 In that regard, antisense oligonucleotides directed to the PDE V isoform was used. The rationale is that the antisense oligonucleotides will base pair with/ bind to the PDE V mRNA and prevent translation of the protein. If true, this strategy would be expected to reduce the amount of the PDE V isozyme available, and therefore, increase the half-life of cGMP. Consistent with such a possibility, the authors reported increased cGMP accumulation/ levels 1-6 h post-transfection, as detected with and ELISA assay. 17 This strategy would again be in the supply-side category of gene transfer techniques.
Gene therapy with CGRP (calcitonin gene-related peptide)
While NO is clearly a major modulator of erectile capacity/function in the normal penis, it is well known that other vasorelaxants are also present and potentially relevant to erectile function. Among the possible suspects, CGRP has long been hypothesized to be such a compound. CGRP is an effector of erectile capacity by virtue of its ability to produce a receptor-mediated increase in intracellular cAMP levels, and a concomitant cellular hyperpolarization via increased K + channel activity. The therapeutic rationale applied here is similar to that described above for the NO cascade, and involves increasing expression of CGRP in order to enhance the cAMPmediated relaxation response in aged rats, thus ameliorating the age-related decline in the NS ICP response. Using an adenoviral-mediated delivery system, Bivalacqua et al 15 were able to document that over-expression of CGRP reversed the agerelated decline in CGRP and cAMP concentrations in the rat corpora, and moreover, produced an increase in the nerve stimulated ICP response to a level equivalent to that of young animals. This effect lasted for up to 5 days, although longer time points were not examined. As such, the precise duration of this therapy is unknown, but nonetheless, it appears that this may represent an attractive therapeutic possibility. The potential long-term side effects, if any, are also not known. Importantly, there were no detectable effects of CGRP overexpression on resting ICP or blood pressure in this series of experiments. Once again, this therapy would fall into the supplyside category of gene transfer techniques.
Gene therapy of RhoA: alterations in calciumsensitization
Calcium sensitization refers to the ability of corporal smooth muscle cells to maintain a tonic contraction in the face of near-resting intracellular calcium levels. This is presumably accomplished largely through the RhoA/Rho kinase pathway. As pointed out in a recent publication, 18 calcium-sensitization mechanisms represent an important component to the tonic contraction of corporal smooth muscle, and thus, flaccidity. In a first attempt to target this system using gene-based approaches, the investigators transfected the corpora with a dominan-negative mutant of RhoA. The strategy here is to increase competition between the endogenously expressed RhoA isoform and the nonfunctional RhoA mutant. This was clearly shown to be the case in this initial report, as both endogeous RhoA and Rho kinase expression were unaltered by the presence of the RhoA mutant. However, transfection with the RhoA mutant in an adeno-associated virus (AAV) vector (again, see Table 1 for details) was associated with a decreased phosphorylation of the regulatory subunit of the myosin light-chain phosphatase, consistent with a decrease in calcium sensitization (ie, an inhibition of an inhibition). The implication is a lower degree of corporal smooth muscle cell tone. In line with the presumed mechanism of action, there was an approximately two-fold increase in basal intracavernous pressure, and moreover, a significant increase in the cavernous nerve stimulated intracavernous pressure response (the ICP/BP ratio approximated unity at the highest levels of stimulation). However, there were no effects on mean arterial pressure, and no evidence of an inflammatory response or other side-effects, at the 1 week time point in these initial studies. The duration examined was 7 days, and the efficacy and side-effect profile of longer time points are currently unknown. However, this initial report clearly shows the importance of this pathway to the erectile process, and moreover, that genetic modification of this pathway can produce quite robust and physiologically relevant alterations in erectile function/capacity. Certainly, this therapy falls into the demand-side category of gene transfer techniques.
Gene therapy with K channels
K channels provide an important mechanism for the regulation of corporal smooth muscle cell tone, [20] [21] [22] [23] and moreover, represent a convergence point for mediating the effects of a wide array of endogenous neurotransmitters, neuromodulators and hormones. As recently pointed out then, K channels are an attractive therapeutic target for both traditional small molecule pharmacology as well as gene-based approaches. 21 To date, we have focused our gene transfer efforts on the a, or pore-forming subunit of the human large conductance, calcium-sensitive K channel (K Ca or maxi-K), referred to as hSlo herein. 5, 21 While the K Ca has been the primary focus of our efforts to date, unpublished data from our group also indicate that gene transfer with the a-subunit of another important K channel subtype, namely Kir6.2 (see Christ 21 for details) might also restore diminished erectile capacity in the aged rat model (Christ et al, unpublished observations). The strategy behind ion channel gene therapy is based on the tight link between K channel activity, transmembrane calcium flux through voltage-dependent calcium channels, and corporal smooth muscle cell tone (see Christ et al, 10 Karicheti and Christ, 20 Christ, 21 , Spektor et al, 22 Melman and Christ
23
). That is, overexpression of hSlo in corporal smooth muscle cells is presumed to increase the hyperpolarizing ability of the syncytial corporal smooth muscle cell network, and by so doing, increase the responsiveness of the erectile apparatus to a nominally diminished supply of endogenous smooth muscle relaxants. The physiological end point is restoration of a degree of corporal smooth muscle relaxation sufficient to result in normal penile erection. The evidence consistent with this supposition has been recently reviewed. 10, [20] [21] [22] [23] Of major importance to this report is the fact that the gene product, namely, the Maxi-K channel, apparently exhibits little or no activity in the corporal smooth muscle cell during flaccidity, 10, 20, 21 but becomes robustly activated by the endogenous erectile second messenger pathways during tumescence. Consistent with the fact that hSlo has little impact on baseline corporal smooth muscle activity, no evidence for the possibility of priapism (ie, increased resting intracavernous pressure) has been observed in our preclinical work. Moreover, as with many of the other gene therapy approaches discussed herein, there is apparently no pathologic effect on corporal tissue histology or architecture (ie, no inflammatory or immune response), nor on mean arterial blood pressure. Another advantage of this gene therapy approach is the apparent longevity of exogenous gene expression. Our published data 10 indicate that the physiologic effects of a single intracorporal injection of hSlo/pcDNA ('naked DNA') can last for up to fourth months. Our most recent data extends this time frame to up to 6 months (Christ and Melman, unpublished observations). In short, this approach seems quite promising, and in fact, this approach was recently reviewed by the NIH RAC (recombinant DNA Advisory Committee), and as such, the submission of an IND application to the FDA for hSlo gene therapy is imminent (see below for more details). Certainly, this therapeutic strategy falls into the demand-side category of gene transfer techniques.
Gene therapy with (BDNF) brain derived neurotrophic factor
The concept behind this therapeutic approach is that increasing the number of nerves, and thereby altering the supply-side of the erectile effector equation, will restore erectile capacity. This approach would be of specific interest to address neuropathic changes that accompany age, diabetes or radical prostate surgery. Thus, Lue and colleagues 16 examined the ability of BDNF gene therapy to restore the cavernous nerve-stimulated ICP response in a rat model of neurogenic impotence. After undergoing a bilateral nerve damage procedure (ie, nerve freezing), rats received an intracavernous injection of (AAV) vector containing the BDNF gene. At 4 and 8 weeks post-injection, rats were examined in functional studies, and corporal tissue was harvested for histological analysis. Briefly, these studies demonstrate that the AAV/BDNF treated group had a significantly elevated nerve stimulate ICP response, which correlated with a significant increase in the number of NOS positive nerve fibers observed. However, it should be pointed out that the time course and magnitude of the measured ICP response was relatively modest/blunted (50-60 cm H 2 O), compared to that observed in the other gene therapy studies reported herein (which were generally more immediate and in the 60-100 cm H 2 O range).This may be a reflection of the intrinsic complexities of neuronal regrowth, and it is conceivable that the magnitude of the increase in ICP may not be sufficient to produce an erection in this model. Nonetheless, these important initial studies do open the door to the possibility of affecting the 'driving force' for erection by manipulating the innervation denisty. Such a possibility has been previously documented on both theoretical and practical 25 grounds, and would represent a real step forward in the understanding and treatment of erectile dysfunction. As noted above, this approach clearly falls on the supply-side category of gene transfer techniques.
Gene therapy with vascular endothelial-derived growth factor (VEGF)
An insufficient vascular supply is thought to be responsible, at least in part, for the etiology of some men with erectile dysfunction. While it seems that in many cases, sufficient corporal smooth muscle relaxation (ie, intracavernous injections) can overcome this deficit, nonetheless, there is a rational basis for expecting that an increased blood flow will aid recovery of erectile function/capacity. Thus, the strategy here is to use an angiogenesis strategy to increase the vascularity of the penis to provide an increased blood flow component to the erectile process. While the number of patients whose erectile dysfunction is soley related to decreased vascularity may be small, a technique that could produce more subtle increases in vascularity might prove to be prophylactic. Moreover, this approach is also quite distinct from those described above, and therefore, worthy of consideration. Although no one has actually published data concerning the efficacy of gene therapy with growth factors, VEGF gene transfer techniques are currently being applied to the treatment of other ischemic cardiovascular diseases such as myocardial ischemia. 26 Moreover, there is a reference 27 to unpublished preclinical studies documenting the utility of genetic targeting of VEGF for the treatment of ED. In addition, another recent study has characterized the VEGF isoforms present in the corpora of humans and rats. 28 Furthermore, consistent with the aforementioned observations, the direct intracorporal injection of VEGF in a rat model of vascular insufficiency had restorative effects on the nerve-stimulated intracavernous pressure response. 29 Although details of the increased/altered vascularity, at the histological level are still lacking, taken together, these data are consistent with the supposition that gene-based approaches using angiogenic factors may be useful in the treatment of erectile dysfunction. The potential pleiotropic actions of this cytokine on multiple cell types (as mentioned for NO above) may provide a significant clinical barrier. Certainly then, this would also be considered to be in the supply-side category of gene transfer techniques.
Cell-based gene therapy
All of the approached described thus far involve genetically modifying the extant cells in the corpora. Another possibility is the (re)-implantation of genetically modified cells into the corpus cavernosum. The strategy here is to 'seed' the penis with cells having the desired, genetically modified, physiological characteristics. Wessells and Williams 30 have established the feasibility of utilizing autologous transplantation of endothelial cells into the corpus cavernosum of the rat. The next step would be to endow these cells with the desired genetic characteristics ex vivo, prior to their reimplantation, in vivo. A similar approach, also in the rat model, has documented the feasibility of using iNOS adenoviral-transfected myoblasts as the delivery vehicle.
14 In this latter instance, increases in the nerve-stimulated ICP response were observed (Table 1) . In this scenario, the newly seeded cells provide an additional reservoir, or supply of endogenous vasorelaxants. With the currently contemplated approaches then, the end result should be a diminished baseline corporal smooth muscle cell tone and/or an enhanced supply or vasorelaxants. Question marks remain concerning the long-term viability of autologously transplanted cells in the corpus cavernosum, as well as the duration of the exogenously transfected gene in these cells redundant. Certainly, this is another exciting approach that would open up additional therapeutic possibilities, and would fall into the supply-side category of gene transfer techniques.
Summary and conclusions
Clearly, all of the preclinical data collected to date are very encouraging. A variety of different techniques have been successfully employed thus far, and therefore, appear worth pursuing. From a clinical standpoint, the major advantages of a gene-based approach are:
1. The potential restoration of normal organ function in the absence of the necessity for any other form of therapy 2. Elimination of the need to 'plan' for sex; that is, it would represent an 'on-demand' therapy. 3. By virtue of the approach taken, even if the therapy itself were not sufficient to restore erectile capacity to normal levels, it is quite clear that a more sensitive corporal smooth muscle cell network (theoretically this is true regardless of the exact target(s)) would be amenable to combination with currently exisiting pharmacological approaches (ie, Viagra). The advantage is that one could then nominally use lower doses of systemic oral medications, thus increasing their efficacy, and nominally, decreasing their sideeffect profile.
As discussed in detail elsewhere, for any and all of the aforementioned reasons, the clinical success of gene therapy would represent a huge step forward in the treatment of erectile dysfunction in particular. [31] [32] [33] [34] [35] [36] In addition, the success of any gene therapy protocol would open the door to the possibility of new treatments for a wide range of human smooth muscle disorders (eg, urinary incontinence, irritable bowel disorders, asthma, premature labor, etc). The remaining hurdle therefore is documentation of safety and efficacy in a human clinical trial. A recent Science article 7 noted that there were 47 naked DNA gene therapy trials being conducted worldwide for various cancers, as well as peripheral artery disease, coronary artery disease, peripheral neuropathy and open bone fractures.
Of particular note at this juncture is the fact that the group in New York (Drs Melman and Christ) has recently made a successful presentation to the NIH RAC (Recombinant DNA Advisory Committee; Human Gene Transfer Protocol #0201-528 entitled: Pilot Study of the Use of the Human hSlo/maxi-K Gene to Treat Erectile Dysfunction). The PDF file summarizing the discussions for this meeting can be found at the following web address: http:// www4.od.nih.gov/oba/RAC/minutes/june02.pdf. A webcast of this is also available at: http://www.webconferences.com/nihoba/20-21_june_02.htm. Formal submission of an IND application to the FDA by this group to begin a Phase I study is now imminent. Hopefully, the safety of this approach, as well as 'proof-of-concept' for the utility/efficacy of gene transfer in the treatment of erectile dysfunction will be forthcoming in the near future.
Note added in Proof
Since submission of the original manuscript, Bivalacqua et al 37 have documented the potential utility of using SOD gene transfer to ameliorate the impact of age-related erectile dysfunction in a rat model of aging in vivo. Their preliminary data, using methods similar to that described previously 11, 12, 15 showed that such gene transfer resulted in significantly elevated SOD levels and corresponding increases in cGMP levels. In turn, the nerve stimulated ICP response in aged rats was restored to levels that were indistinguishable from that observed in young rats. A single time point was examined (ie, 1 day). This report would also be classified on the supply-side of the gene therapy strategies thus far utilized, as the overall effect would be an increased bioavailability of nitric oxide (NO).
